close
Enquiry IconContact Us
Logo
  • Choose License Type

Global Antibody Drug Conjugates Market, by Drug Name (Adcetris, Kadcyla, Besponsa, Lumoxiti, Mylotarg, and Others), by Application (Blood Cancer, Breast Cancer, Urothelial & Bladder Cancer, and Other Types of Cancer), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 4.29  billion in 2021, and is expected to exhibit a CAGR of  14.0%  during the forecast period (2021-2028).

Increasing number of research and development activities is expected to help in boosting growth of the global antibody drug conjugates market. For instance, on November 05, 2020, CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, announced that the first patient in the Phase II expansion study of CX-2029, an anti-CD71 Probody drug conjugate, had been treated. The study, which is being conducted in collaboration with AbbVie, a U.S. based biopharmaceutical company, is evaluating CX-2029 as monotherapy in four cohorts: squamous non-small cell lung cancer (sqNSCLC), squamous head and neck cancer (sqHNSCC), esophageal cancer, and diffuse large B-cell lymphoma (DLBCL).

Increase in number of acquisitions, partnerships, and collaborations between the market players is expected to propel the growth of the global antibody drug conjugates market during the forecast period. For instance, on December 10, 2020, Boehringer Ingelheim signed a binding agreement to acquire all of the shares of NBE-Therapeutics, a private, clinical-stage Swiss Biotechnology Company focused on antibody-drug conjugates (ADC). NBE-002, the lead compound of NBE-Therapeutics, is currently in phase I clinical trials for triple negative breast cancer and other solid tumors. This acquisition allows Boehringer Ingelheim to obtain an innovative and unique platform that will build a leading ADC product portfolio and develop possible combinations with other assets from its cancer immunology product portfolio.

Global Antibody Drug Conjugates Market- Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic has affected several markets across the globe. The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and due to its financial impact on firms and financial markets. Thus, impact of the coronavirus (COVID-19) pandemic is expected to hinder the growth of the global antibody drug conjugates market. For instance, according to the article published in the journal of JCO Global Oncology, September 2020, between April 21 and May 8, 2020, 356 centers from 54 countries across six continents took part in the study. Every year, 716,979 new cancer patients are treated at these facilities. During the pandemic, the majority of them (88.2 %) reported difficulties in providing cancer care. The study's findings conclude that the COVID-19 pandemic's negative impact on cancer care is widespread, with varying magnitudes across centers worldwide.

Browse 35 Market Data Tables and 25 Figures spread through 210 Pages and in-depth TOC on Global Antibody Drug Conjugates Market, by Drug Name (Adcetris, Kadcyla, Besponsa, Lumoxiti, Mylotarg, and Others), by Application (Blood Cancer, Breast Cancer, Urothelial & Bladder Cancer, and Other Types of Cancer), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Antibody Drug Conjugates Market, click the link below:

 https://www.coherentmarketinsights.com/market-insight/antibody-drug-conjugates-market-181

Key Takeaways of the Global Antibody Drug Conjugates Market:

  • The global antibody drug conjugates market is expected to exhibit a CAGR of 14.0 % over the forecast period (2021-2028). North America is expected to account for major market share over the forecast period (2021-2028), owing to the rising product approvals by regulatory authorities. For instance, on December 18, 2019, Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, was granted accelerated approval by the U.S. Food and Drug Administration (FDA), indicating that the drug specifically targets cancer cells – in this case, the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers. Padcev is developed by Astellas Pharma U.S. Inc., a Japanese multinational pharmaceutical company.
  • Some of the major players operating in the global antibody drug conjugates market include F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Ltd., Astellas Pharma, ADC Therapeutics, Pfizer, Inc., Seagen, Inc., Daiichi Sankyo Company Ltd., and Oxford Biotherapeutics.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.